TrialNCT07222137
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
- Status
- RECRUITING
- Phase
- PHASE3
- Last update posted
- 09/04/2026
- Start
- 01/12/2026
- Sponsor
- Eli Lilly and Company
- Specialties
- diabetes
Conditions: Diabetes Mellitus, Type 1
Brief summary
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.